MoonLake hopes another phase 2 win helps IL-17 drug shine brighter in inflammatory race

MoonLake Immunotherapeutics is hoping to maintain its position as a key player in the race to get an IL-17 inhibitor to market for inflammatory skin conditions courtesy of another phase 2 readout the biotech touted as a success.